| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
| 2016 | AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. | Li, CW ; Xia, W; Lim, SO; Hsu, JL; Huo, L; Wu, Y; Li, LY; Lai, CC; Chang, SS; Hsu, YH; Sun, HL; Kim, J; Yamaguchi, H; Lee, DF; Wang, H; Wang, Y; Chou, CK; Hsu, JM; Lai, YJ; LaBaff, AM; Ding, Q; Ko, HW; Tsai, FJ; Tsai, CH; Hortobagyi, GN; Hung, MC | Cancer research 76(6), 1451-1462 | | | |
| 2014 | Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. | Hsu, YH; Yao, J; Chan, LC; Wu, TJ; Hsu, JL; Fang, YF; Wei, Y; Wu, Y; Huang, WC; Liu, CL; Chang, YC; Wang, MY; Li, CW ; Shen, J; Chen, MK; Sahin, AA; Sood, A; Mills, GB; Yu, D; Hortobagyi, GN; Hung, MC | Cancer research 74(17), 4822-4835 | | | |
| 2016 | Deubiquitination and Stabilization of PD-L1 by CSN5. | Lim, SO; Li, CW ; Xia, W; Cha, JH; Chan, LC; Wu, Y; Chang, SS; Lin, WC; Hsu, JM; Hsu, YH; Kim, T; Chang, WC; Hsu, JL; Yamaguchi, H; Ding, Q; Wang, Y; Yang, Y; Chen, CH; Sahin, AA; Yu, D; Hortobagyi, GN; Hung, MC | Cancer cell 30(6), 925-939 | | | |
| 2016 | EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. | Lim, SO; Li, CW ; Xia, W; Lee, HH; Chang, SS; Shen, J; Hsu, JL; Raftery, D; Djukovic, D; Gu, H; Chang, WC; Wang, HL; Chen, ML; Huo, L; Chen, CH; Wu, Y; Sahin, A; Hanash, SM; Hortobagyi, GN; Hung, MC | Cancer research 76(5), 1284-1296 | | | |
| 2012 | Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. | Li, CW ; Xia, W; Huo, L; Lim, SO; Wu, Y; Hsu, JL; Chao, CH; Yamaguchi, H; Yang, NK; Ding, Q; Wang, Y; Lai, YJ; LaBaff, AM; Wu, TJ; Lin, BR; Yang, MH; Hortobagyi, GN; Hung, MC | Cancer research 72(5), 1290-1300 | | | |
| 2018 | Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. | Li, CW; Lim, SO; Chung, EM; Kim, YS; Park, AH; Yao, J; Cha, JH; Xia, W; Chan, LC; Kim, T; Chang, SS; Lee, HH; Chou, CK; Liu, YL; Yeh, HC; Perillo, EP; Dunn, AK; Kuo, CW; Khoo, KH ; Hsu, JL; Wu, Y; Hsu, JM; Yamaguchi, H; Huang, TH; Sahin, AA; Hortobagyi, GN; Yoo, SS; Hung, MC | Cancer cell 33(2), 187-201.e10 | | | |
| 2011 | FOXO3a dependent mechanism of E1A-Induced chemosensitization. | Su, JL; Cheng, X; Yamaguchi, H; Chang, YW; Hou, CF; Lee, DF; Ko, HW; Hua, KT; Wang, YN; Hsiao, M; Chen, PB; Hsu, JM; Bast, RC; Hortobagyi, GN; Hung, MC | Cancer Res Nov. 1;71(21):6878-6887. Cite 1 | | | |
| 2016 | Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. | Li, CW ; Lim, SO; Xia, W; Lee, HH; Chan, LC; Kuo, CW; Khoo, KH ; Chang, SS; Cha, JH; Kim, T; Hsu, JL; Wu, Y; Hsu, JM; Yamaguchi, H; Ding, Q; Wang, Y; Yao, J; Lee, CC; Wu, HJ; Sahin, AA; Allison, JP; Yu, D; Hortobagyi, GN; Hung, MC | Nature communications 7, 12632 | | | |
| 2017 | PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. | Jiao, S; Xia, W; Yamaguchi, H; Wei, Y; Chen, MK; Hsu, JM; Hsu, JL; Yu, WH; Du, Y; Lee, HH; Li, CW ; Chou, CK; Lim, SO; Chang, SS; Litton, J; Arun, B; Hortobagyi, GN; Hung, MC | Clinical cancer research : an official journal of the American Association for Cancer Research 23(14), 3711-3720 | | | |
| 2019 | Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. | Han, Y; Chen, MK; Wang, HL; Hsu, JL; Li, CW ; Chu, YY; Liu, CX; Nie, L; Chan, LC; Yam, C; Wang, SC; He, GJ; Hortobagyi, GN; Tan, XD; Hung, MC | American journal of cancer research 9(3), 608-618 | | | |
